author-photo

Abbie Oey

5

Papers

14

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors

2018 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (8)
Safety, Tolerability and Pharmacokinetics (PK) Following Single and Multiple Ascending Dosing of AL-8176 in Healthy Volunteers (HV)

2015 Open Forum Infectious Diseases
Show All
- Source
- Cite
- Save
Citations (1)
Abstract C18: A phase I study of enavatuzumab (PDL192, ABT-361), a first-in-class human monoclonal antibody targeting TWEAK (tumor necrosis factor-like inducer of apoptosis) receptor, in patients (Pts) with advanced solid tumors.

2011 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (1)